Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Publications
▹
Home
Publication
Nerve growth factor/p38 signaling increases intraepidermal nerve fiber densities
in painful neuropathy of type 2 diabetes.
Authors
Cheng HT, Dauch JR, Hayes JM, Yanik BM, Feldman EL
Submitted By
Eva Feldman on 2/22/2012
Status
Published
Journal
Neurobiology of disease
Year
2012
Date Published
1/1/2012
Volume : Pages
45 : 280 - 287
PubMed Reference
21872660
Abstract
Painful diabetic neuropathy (PDN) is a common, yet devastating complication of
type 2 diabetes. At this time, there is no objective test for diagnosing PDN. In
the current study, we measured the peptidergic intraepidermal nerve fiber
densities (IENFD) from hind paws of the db/db mouse, an animal model for type 2
diabetes, during the period of mechanical allodynia from 6 to 12 weeks of age.
Intraepidermal nerve fibers (IENF) of the hind footpads were identified by
protein gene product (PGP) 9.5 immunohistochemistry. The peptidergic IENF were
determined by double immunofluorescence using anti-PGP9.5 and antibodies against
tropomyosin-receptor-kinase (Trk) A. We observed a significant increase in
PGP9.5-positive IENFD at 8 and 10 weeks of age. Similarly, Trk A-positive
peptidergic IENF, which also express substance P and calcitonin gene related
peptide in db/db mice, were observed to be elevated from 1.5 to 2 fold over
controls. This upregulation ended at 16 weeks of age, in accordance with the
reduction of mechanical allodynia. Anti-NGF treatment significantly inhibited
the upregulation of peptidergic IENFD during the period of mechanical allodynia,
suggesting that increased neurotrophism may mediate this phenomenon. In
addition, SB203580, an inhibitor of p38, blocked the increase in peptidergic
IENFD in db/db mice. The current results suggest that peptidergic IENFD could be
a potential diagnostic indicator for PDN in type 2 diabetes. Furthermore, the
inhibition of NGF-p38 signaling could be a potential therapeutic strategy for
treating this painful condition.
Investigators with authorship
Name
Institution
Eva Feldman
University of Michigan
Complications
All Complications
Bioinformatics
Bone
Cardiomyopathy
Cardiovascular
Gastro-Intestinal (GI)
Nephropathy
Neuropathy & Neurocognition
Pediatric Endocrinology
Retinopathy
Uropathy
Wound Healing
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!